


FIGURE 2



TISSUE WEIGHT

/ild Type

WG	30.4	0.543	三0:141	0.204	1	100	1.79	. 0.46	0.67
SEM	0.54	0.129	0.002	0.011			0.46	0.01	0.02
	BW	WAT	BAT	QUAD		BW	WAT	BAT	ONAD

Cbl-deficient


0.07 WAT	4VG	30.00	0.226	0.073	0.206	1000	00.00	0.75	0.24	0.69
WAT BAT QUAD BW WAT	_	0.95	0.021	0.005	0.013			0.07	0.01	0.04
		BW	WAT	BAT	QUAD		BW	WAT	BAT	QUAD

FIGURE 4

# BEST AVAILABLE COPY

5/37

Wild Type



**Cbl-deficient** 




FIGURE 5

6/37


ADIPOCYTE SIZE MALES

	diameter (μm)	(1	VOLUME (pl/cell)		Lipid content (ng/cell)	(ng/cell)
	AVG	SEM	AVG	SEM	AVG	SEM
TW	84.91	1.57	240.28	4.45	219.86	4.07
КО	49.44	06:0	82.43	1.25	75.42	1.14
KO 500	56.82	1.23	72	1.56	65.88	1.43

ADIPOCYTE SIZE FEMALES


	diameter (μm)		VOLUME (pl/cell)		Lipid content (ng/cell)	(ng/cell)
	AVG	SEM	AVG ·	SEM	AVG	SEM
TW	80.48	2.32	204.6	5.9	187.3	5.4
КО	55.21	1.77	66.05	2.12	60.92	1.96

FIGURE 6



TOTAL COTY





BEST AVAILABLE COPY

9/37




FIGURE 7c

ALION STANFARMANA A ASIG

BEST AVAILABLE COPY

10/37




FIGURE 8a

11/37




FIGURE 8b

12/37




FIGURE 8c

13/37




FIGURE 8d




FIGURE 8e

15/37




FIGURE 9




FIGURE 10a




FIGURE 10b

18/37




FIGURE 10c

BEST AVAILABLE COPY

19/37




FIGURE 10d

# 20/37




FIGURE 10e

BEST AVAILARIE COPY

# 21/37




FIGURE 10f

BEST AVAILABLE COPY




FIGURE 11a

23/37





FIGURE 11b



**'IGURE 11**0




FIGURE 11d

26/37

shRNA

lipof GFP c-Cbl


α c-Cbl



Q

FIGURE 12a

27/37



BEST AVAILABLE COPY

# 28/37

RNAi agent for delivery



Formulate agent with carrier



Select delivery vehicle for carrier/agent



Construct delivery vehicle/ carrier/agent device



Implant device at appropriate location in or adjacent to vascular tissue

Figure 13

29/37

20

-Promoter-shRNA-Terminator-

10

Figure 14a

20

- Promoter 1-ddRNA sense-Terminator 1- Promoter 2-ddRNA antisense-Terminator 2

10

Figure 14b






Figure 14c





-Igure 14










Figure 15b

34/37

P3— siRNA3sense——T3-M- 3' . —24 P2— siRNA2sense— T2— T5\_\_ siRNA2a/s\_ 5' -M- P1-- siRNA1sense--3' -M T4\_ siRNA1a/s \_\_

Figure 15c




Figure 15d




FIGURE 16a




FIGURE 16b